Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.73 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.73 |
| ▸ | PRKCG | P05129 | 2/20 | 0.73 |
| ▸ | PRKCB | P05771 | 2/20 | 0.73 |
| ▸ | PRKCA | P17252 | 2/20 | 0.73 |
| ▸ | PRKCH | P24723 | 2/20 | 0.73 |
| ▸ | PRKCI | P41743 | 2/20 | 0.73 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.73 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.73 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.73 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.73 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | GMNN | O75496 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447847 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL27603790 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL12380305 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL8257173 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL8251942 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL23016734 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL4177817 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL1962471 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL28728461 | 0.94 | AKT1 (0.65) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL28728460 | 0.94 | AKT1 (0.65) | AKT1PRKD3PRKCGPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103058-A1 | NOVEL COMPOUNDS AS MYT1 INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026103103-A1 | NOVEL COMPOUNDS AS MYT1 INHIBITORS AND USES THEREOF | PEKING UNION MEDICAL COLLEGE HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE (CN) | 2026-05-21 | — | — | WO | disclosed |
| US-12600771-B2 | Antibody for binding to interleukin 4 receptor | CONNECT BIOPHARMA HONGKONG LIMITED (HK) | 2026-04-14 | — | — | US | disclosed |
| US-20250382386-A1 | ANTI-ALK-1 ANTIBODY AND USE THEREOF | KINTOR PHARMACEUTICAL (GUANGDONG) CO., LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| EP-4653466-A1 | ANTI-ALK-1 ANTIBODY AND USE THEREOF | KINTOR PHARMACEUTICAL (GUANGDONG) CO., LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4624469-A1 | QUINOLINE AMINE COMPOUND CRYSTAL FORM AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20250235496-A1 | USE OF BELLIDIFOLIN (BEL) AND/OR BEL-CONTAINING EXTRACT IN PREPARATION OF ANTIDEPRESSANT PRODUCT | NORTHWEST INSTITUTE OF PLATEAU BIOLOGY, CAS (CN) | 2025-07-24 | — | — | US | disclosed |
| US-20250066458-A1 | Bispecific Antibodies Specifically Binding to Klebsiella Pneumoniae O2 Antigen and O1 Antigen and Compositions Thereof | Beijing Solobio Genetechnology Co., Ltd. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4445911-A1 | BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO KLEBSIELLA PNEUMONIAE O2 AND O1 ANTIGENS, AND COMPOSITION | Beijing SoloBio Genetechnology Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-20240327388-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-114805400-A | Dihydropurine thioketone derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022148822-A1 | USP5 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF | LOCKI THERAPEUTICS LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022135360-A1 | PURINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022135555-A1 | PURINONE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-114656487-A | Condensed pyrimidine compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114656486-A | Purine ketone compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114634522-A | Purine ketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114592047-A | Method for detecting circulating tumor cells and application thereof | 中国科学院苏州生物医学工程技术研究所 | 2022-06-07 | — | — | CN | disclosed |
| CN-114539356-A | Lipopeptide and preparation method and application thereof | 中国人民解放军陆军军医大学 | 2022-05-27 | — | — | CN | disclosed |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | BEBETTER MED INC. (CN) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | EGFR, ERBB2, KRAS | AKT1 1122/4885PRKD3 3173/4885PRKCG 2130/4885 |
| US-20250235496-A1 | USE OF BELLIDIFOLIN (BEL) AND/OR BEL-CONTAINING EXTRACT IN PREPARATION OF ANTIDEPRESSANT PRODUCT | CRH, GAP43, CHRNB3 | AKT1 1902/4885PRKD3 1302/4885PRKCG 2150/4885 |
| US-20240327388-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | QARS1, THEM6, CYP4F11 | AKT1 2525/4885PRKD3 4643/4885PRKCG 4612/4885 |
| US-12600771-B2 | Antibody for binding to interleukin 4 receptor | IGLV6-57, VSIG8, IL4 | AKT1 4280/4885PRKD3 2919/4885PRKCG 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.